Nuwellis, Inc. — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Nuwellis (NUWE), a $4.6M market-cap company, presented November 2026 investor materials showing YTD 2026 revenue growth of 13% versus prior year, with gross margins improving to 72% from 59%. The company reports ~$6.6M YTD Q3 2026 revenue, ~135 active hospital accounts (10% of target), and 47 installations in leading U.S. children's hospitals. The company has $8.3M cash as of September 30, 2026, with runway through Q2 2027. Pipeline includes: FDA 510(k) submission for pediatric indication (5kg from 20kg), co-promotion of AtriAmp cardiac monitoring, Zorro-Flow distribution (Q1 2027), ClarityPRIME monitoring platform (H2 2027), and next-gen Vivian pediatric platform (2028/2029, backed by $3M NIH grant). Pediatrics represents ~50% of revenue.
Why this rating
13% revenue growth + 13-point margin expansion + $8.3M cash + multi-product pipeline is material for $4.6M company. Near-term milestones concrete. Cash runway Q2 2027 is constraint.
Tradability signal
NO TRADE
No trade: only ~$49k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $4.45 | +10 min · unknown $4.26 ▼ 4.27% | +30 min · unknown $4.26 ▼ 4.27% | +1 hr · unknown $4.26 ▼ 4.27% | +4 hrs · unknown $4.25 ▼ 4.49% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.